68 related articles for article (PubMed ID: 20585871)
1. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of the Immunohistochemical Expression of Histone Deacetylases (HDACs)-2, -4, and -5 in Ovarian Adenocarcinomas.
Levidou G; Arsenakis D; Bolovis DI; Meyer R; Brucker CVM; Papadopoulos T; Theocharis S
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790909
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the Mysterious Relationship between the Cross-Pathogenetic Mechanisms of Neurodegenerative and Oncological Diseases.
Aleksandrova Y; Neganova M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834214
[TBL] [Abstract][Full Text] [Related]
4. Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets.
Liu R; Wu J; Guo H; Yao W; Li S; Lu Y; Jia Y; Liang X; Tang J; Zhang H
MedComm (2020); 2023 Jun; 4(3):e292. PubMed ID: 37220590
[TBL] [Abstract][Full Text] [Related]
5. The Epigenesis of Salivary Glands Carcinoma: From Field Cancerization to Carcinogenesis.
Mat Lazim N; Yousaf A; Abusalah MAH; Sulong S; Mohd Ismail ZI; Mohamud R; Abu-Harirah HA; AlRamadneh TN; Hassan R; Abdullah B
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046772
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
Badie A; Gaiddon C; Mellitzer G
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358890
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma.
Palamaris K; Moutafi M; Gakiopoulou H; Theocharis S
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409020
[TBL] [Abstract][Full Text] [Related]
8. Correlation Analysis of Protein Expression of 10 HDAC/Sirtuin Isoenzymes with Sensitivities of 23 Anticancer Drugs in 17 Cancer Cell Lines and Potentiation of Drug Activity by Co-Treatment with HDAC Inhibitors.
Behnisch-Cornwell S; Grathwol CW; Schulig L; Voigt A; Baecker D; Link A; Bednarski PJ
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008351
[TBL] [Abstract][Full Text] [Related]
9. E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors.
Decourtye-Espiard L; Bougen-Zhukov N; Godwin T; Brew T; Schulpen E; Black MA; Guilford P
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008338
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients' Survival.
Levidou G; Gajdzis P; Cassoux N; Donizy P; Masaoutis C; Gajdzis M; Gardrat S; Pergaris A; Danas E; Klijanienko J; Theocharis S
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638249
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia.
Goutas D; Theocharis S; Tsourouflis G
Diagnostics (Basel); 2021 Jul; 11(8):. PubMed ID: 34441281
[TBL] [Abstract][Full Text] [Related]
12. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors.
Pouloudi D; Manou M; Sarantis P; Tsoukalas N; Tsourouflis G; Dana E; Karamouzis MV; Klijanienko J; Theocharis S
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33799478
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis.
Zhang W; Zhang Y; Tu T; Schmull S; Han Y; Wang W; Li H
Cell Death Dis; 2020 Sep; 11(9):765. PubMed ID: 32943605
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities.
Canale M; Casadei-Gardini A; Ulivi P; Arechederra M; Berasain C; Lollini PL; Fernández-Barrena MG; Avila MA
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752096
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Li H; Li H; Waresijiang Y; Chen Y; Li Y; Yu L; Li Y; Liu L
Exp Ther Med; 2020 Jul; 20(1):315-324. PubMed ID: 32536999
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
18. HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.
Spaety ME; Gries A; Badie A; Venkatasamy A; Romain B; Orvain C; Yanagihara K; Okamoto K; Jung AC; Mellitzer G; Pfeffer S; Gaiddon C
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31703394
[TBL] [Abstract][Full Text] [Related]
19. Role of HDAC1 in the progression of gastric cancer and the correlation with lncRNAs.
Yu Z; Zeng J; Liu H; Wang T; Yu Z; Chen J
Oncol Lett; 2019 Mar; 17(3):3296-3304. PubMed ID: 30867763
[TBL] [Abstract][Full Text] [Related]
20. Expression profiles of histone modification genes in gastric cancer progression.
Orenay-Boyacioglu S; Kasap E; Gerceker E; Yuceyar H; Demirci U; Bilgic F; Korkmaz M
Mol Biol Rep; 2018 Dec; 45(6):2275-2282. PubMed ID: 30250993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
